Latest Earnings
Equities
Stock Analysis
Stock Movers
Deals
Gainers And Losers
IPOs
Technology
Artificial Intelligence
Web Stories
Benzinga Inspire
Cipla
Cipla Skyrockets Over 8% After Dodging Major U.S. Regulatory Hurdle, Paving Way For Much-Awaited Drug Launch
This is a major relief for the pharmaceutical industry company as it paves the way for an earlier-than-expected approval and launch of cancer drug gAbraxane.
Cipla's Q2 Net Profit Climbs 15.2% To ₹1,302.53 Cr, Beats Estimates
Cipla Shares Shoot Up After Q1 Profit Goes Up 18% To Beat Estimates As U.S. Business Shines
Cipla Skyrockets Over 8% After Dodging Major U.S. Regulatory Hurdle, Paving Way For Much-Awaited Drug Launch
Cipla's Q2 Net Profit Climbs 15.2% To ₹1,302.53 Cr, Beats Estimates
Cipla Shares Shoot Up After Q1 Profit Goes Up 18% To Beat Estimates As U.S. Business Shines
Cipla Shares Soar 4% After Promoters Sell Stake
|
Cipla shares zoomed 4% on Wednesday after the company's promoters sold over 2% stake in the company.
Cipla Shares Soar 6% As Q4 Numbers Impresses Brokearges, Investors
|
Cipla's share price was surging at the bourses on Monday after the company's March quarter results impressed investors. The stock went up 6% to hit an intraday high of ₹1,425.95.
